<DOC>
	<DOCNO>NCT00400478</DOCNO>
	<brief_summary>This randomize , open label , phase III study evaluate ability rituximab maintenance therapy prolong event-free survival aggressive NHL . Patients screen successful standard induction therapy ( CR Cru follow standard R-CHOP-like therapy 8 infusion rituximab plus CHOP-like chemotherapy ( 4-8 cycle ) . Patients follow event occurs define protocol . To evaluate clinical efficacy rituximab maintenance therapy compare observation patient aggressive B-cell Non-Hodgkins lymphoma follicular lymphoma grade 3b achieve complete remission appropriate first-line therapy , measure event-free survival ( EFS ) , 440 patient DLCBL follicular NHL grade 3 ( 220 per arm ) recruit .</brief_summary>
	<brief_title>A Multicentre , Randomized Phase III Study Rituximab Maintenance Treatment Versus Observation Patients With Aggressive B-cell Lymphoma : NHL-13</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>4 8 cycle RCHOP/like , total 8x Rituximab CR , CRu ECOG/ 0.1 2 Known IPI time diagnosis Age &gt; 18 year Negative pregnancy test Men must agree father child therapy Transformed lymphoma Secondary malignancy Evidence CNS involvement Significant cardiac disease Creatinine &gt; 2.0 mg/dl HIV , Hepatitis positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>NHL 13</keyword>
	<keyword>Rituximab</keyword>
	<keyword>maintenance</keyword>
</DOC>